<DOC>
	<DOCNO>NCT01042769</DOCNO>
	<brief_summary>This double-blind , parallel , two-arm study evaluate potential reduce cardiovascular risk , tolerability long-term safety profile aleglitazar compare placebo top standard care patient recent acute coronary syndrome ( ACS ) type 2 diabetes mellitus . Patients randomize receive either aleglitazar placebo daily oral dos . The study last least 950 event occur , time study treatment least 2.5 year .</brief_summary>
	<brief_title>A Study With Aleglitazar Patients With Recent Acute Coronary Syndrome Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Adults &gt; 18 year age Type 2 diabetes mellitus Hospitalization ACS event randomization hospital discharge 8 week ACS index event ( day hospitalization ) Estimated glomerular filtration rate &lt; 45 mL/min/1.73m2 Concomitant treatment thiazolidinedione and/or fibrate Triglycerides &gt; 400 mg/dL Anaemia Symptomatic congestive heart failure classify New York Heart Association ( NYHA ) class IIIV ( France Germany : Symptomatic congestive heart failure classify NYHA class IIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>